Datamonitor estimates the antidyslipidemic drug-treated population at 53.2 million patients in the Chinese market, with obesity and diabetes the most common co-morbidities. Statins are the dominant treatment for high cholesterol while fibrates are more used for hypertriglyceridemia. Traditional Chinese medicines are the second most popular choice to treat hypercholesterolemia.
Features and benefits
Highlights
Not all patients are available for drug treatment due to the low diagnosis rate, low compliance rates, and therapeutic lifestyle management as the first line of treatment. Only 43% of dyslipidemia patients are reported diagnosed in China.
In China, statins dominate treatment regimens (monotherapies and combination therapies) for both pure hypercholesterolemia (82% of patients) and mixed hyperlipidemia (76% of patients).
The extremely low awareness of dyslipidemia was reflected in Datamonitor's physician survey, in which physicians put "more studies to provide evidence" and "improve patient awareness" on top of the list of unmet clinical needs.
Your key questions answered